Literature DB >> 24045110

Perturbation of biogenesis and targeting of Epstein-Barr virus-encoded miR-BART3 microRNA by adenosine-to-inosine editing.

Ting Lei1,2, Kit-San Yuen1, Sai Wah Tsao3, Honglin Chen4, Kin-Hang Kok1, Dong-Yan Jin1.   

Abstract

Epstein-Barr virus (EBV) encodes at least 44 mature microRNAs (miRNAs), some of which are abundantly expressed in nasopharyngeal carcinoma cells. EBV-encoded miR-BART6 miRNA is known to undergo adenosine-to-inosine (A-to-I) RNA editing, which impacts on processing and function. Whether additional EBV miRNAs might be A-to-I edited remains to be determined. In this study, we have reported on A-to-I editing of EBV miR-BART3. The A-to-I editing enzyme was expressed abundantly in EBV-infected epithelial carcinoma cells. pri-miR-BART3 was found to be edited at four sites in these cells and in nasopharyngeal carcinoma samples. Whereas editing of the second site located within the seed region prevented the targeting of DICE1 mRNA, editing of the third site effectively crippled the biogenesis of mature miR-BART3. Thus, A-to-I editing perturbs biogenesis and targeting of miR-BART3 and may contribute to its differential expression and function in EBV-infected epithelial cells.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24045110     DOI: 10.1099/vir.0.056226-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  10 in total

1.  New Noncoding Lytic Transcripts Derived from the Epstein-Barr Virus Latency Origin of Replication, oriP, Are Hyperedited, Bind the Paraspeckle Protein, NONO/p54nrb, and Support Viral Lytic Transcription.

Authors:  Subing Cao; Walter Moss; Tina O'Grady; Monica Concha; Michael J Strong; Xia Wang; Yi Yu; Melody Baddoo; Kun Zhang; Claire Fewell; Zhen Lin; Yan Dong; Erik K Flemington
Journal:  J Virol       Date:  2015-04-29       Impact factor: 5.103

Review 2.  A-to-I editing of coding and non-coding RNAs by ADARs.

Authors:  Kazuko Nishikura
Journal:  Nat Rev Mol Cell Biol       Date:  2015-12-09       Impact factor: 94.444

3.  PACT- and RIG-I-Dependent Activation of Type I Interferon Production by a Defective Interfering RNA Derived from Measles Virus Vaccine.

Authors:  Ting-Hin Ho; Chun Kew; Pak-Yin Lui; Chi-Ping Chan; Takashi Satoh; Shizuo Akira; Dong-Yan Jin; Kin-Hang Kok
Journal:  J Virol       Date:  2015-11-25       Impact factor: 5.103

Review 4.  ADAR enzyme and miRNA story: a nucleotide that can make the difference.

Authors:  Sara Tomaselli; Barbara Bonamassa; Anna Alisi; Valerio Nobili; Franco Locatelli; Angela Gallo
Journal:  Int J Mol Sci       Date:  2013-11-19       Impact factor: 5.923

Review 5.  Regulation of viral oncogenesis by microRNAs.

Authors:  Xiaojie Xu; Qinong Ye
Journal:  Mol Cell Oncol       Date:  2014-09-02

6.  Difference in microRNA expression and editing profile of lung tissues from different pig breeds related to immune responses to HP-PRRSV.

Authors:  Jia Li; Zhisheng Chen; Junlong Zhao; Liurong Fang; Rui Fang; Jiang Xiao; Xing Chen; Ao Zhou; Yingyin Zhang; Liming Ren; Xiaoxiang Hu; Yaofeng Zhao; Shujun Zhang; Ning Li
Journal:  Sci Rep       Date:  2015-04-09       Impact factor: 4.379

Review 7.  BART miRNAs: an unimaginable force in the development of nasopharyngeal carcinoma.

Authors:  Youhong Wang; Zhen Guo; Yan Shu; Honghao Zhou; Hui Wang; Wei Zhang
Journal:  Eur J Cancer Prev       Date:  2017-03       Impact factor: 2.497

Review 8.  The Role of miRNAs in Virus-Mediated Oncogenesis.

Authors:  Zuzana Vojtechova; Ruth Tachezy
Journal:  Int J Mol Sci       Date:  2018-04-17       Impact factor: 5.923

Review 9.  Viral Encoded miRNAs in Tumorigenesis: Theranostic Opportunities in Precision Oncology.

Authors:  Rodney Hull; Rahaba Marima; Mohammed Alaouna; Demetra Demetriou; Rui Manuel Reis; Thulo Molefi; Zodwa Dlamini
Journal:  Microorganisms       Date:  2022-07-18

Review 10.  The impact of RNA modifications on the biology of DNA virus infection.

Authors:  Suba Rajendren; John Karijolich
Journal:  Eur J Cell Biol       Date:  2022-05-21       Impact factor: 6.020

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.